AN OPEN LETTER TO THE SCIENTIFIC COMMUNITY ON THE POSSIBLE ROLE OF DYSREGULATED BRADYKININ SIGNALING IN COVID-19 RESPIRATORY COMPLICATIONS
journal contributionposted on 16.04.2020, 04:41 by Joseph Roche, Renuka Roche
Any type of content formally published in an academic journal, usually following a peer-review process.
In this Open Letter to the Scientific Community, we propose a model for dysregulated bradykinin signaling in COVID-19 respiratory complications. Based on our model, we suggest the off-label and compassionate use of the FDA-approved bradykinin receptor blocker, icatibant, for patients with unremitting respiratory distress from COVID-19.